Patheon invests in key sites to support continued growth

Global provider of drug development and delivery solutions to the pharmaceutical sector, Patheon, has revealed it is anticipating to invest approximately $45 million at key sites worldwide to meet growing customer demand for expanded service capabilities.

“As outsourcing of pharma development and manufacturing services continues to grow, our customers will need even more advanced technologies and customised solutions to meet their business needs,” said Michel Lagarde, president of Patheon. “With the increasing marketplace pressures, pharma companies are looking to build more reliable, flexible and cost-efficient supply chains. With our focus on people, process and capabilities, Patheon is uniquely positioned to partner with pharma companies to achieve their objectives — cost effectively while delivering the highest quality.”

The company will be investing in the key areas: commercial and development spray drying and flexible manufacturing solutions. The former area investments will include additional commercial spray drying capabilities to Patheon’s site in Florence, South Carolina, which will complement the low-solubility centre of excellence located in Bend, Oregon. Additionally, the Bend site will see an expansion of the existing development spray-dried dispersion (SDD) capabilities with a new cGMP analytical lab, manufacturing suite and additional development scale spray drying.

In the area of flexible management solutions, Patheon has invested in a new commercial sterile product manufacturing facility in its Monza, Italy site. It also plans to expand its sterile Pharmaceutical Development Services (PDS) at the Italian site and will expand its packaging and serialisation capabilities at its Greenville, North Carolina site.